Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript

At the Goldman Sachs Global Healthcare Conference, Regeneron's CFO Christopher Fenimore outlined the company's strategic priorities for the next 12-18 months, emphasizing execution on core strategies amid EYLEA franchise dynamics, the Dupixent outlook, and the late-stage pipeline; specific details on these strategies were not provided in this excerpt.

Analysis

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) executives, Christopher R. Fenimore (CFO) and Ryan Crowe (Head of IR), participated in a question-and-answer session at the 46th Annual Goldman Sachs Global Healthcare Conference on June 9, 2025. The discussion was framed by Goldman Sachs analyst Salveen Jaswal Richter to address Regeneron's strategic positioning over the next 12 to 18 months, specifically concerning the EYLEA franchise dynamics, the outlook for Dupixent, and developments in its late-stage pipeline. Prior to addressing these strategic elements, Ryan Crowe delivered a standard forward-looking statements disclaimer, reminding attendees of inherent risks and uncertainties and that the company does not commit to updating such statements. The provided text excerpt, however, concludes before the CFO, Christopher Fenimore, offers any specific details regarding these strategic priorities or execution plans. Consequently, this segment primarily sets the agenda for the discussion rather than conveying new material information or specific financial guidance, which is reflected in the neutral sentiment score (0.0) and low market impact score (0.05) associated with this initial communication.

Key Decisions for Investors

• Investors should note that this conference excerpt only provides the context for Regeneron's strategic discussion and does not contain substantive new information on EYLEA, Dupixent, or pipeline progress.
• It is advisable to seek the full conference transcript or subsequent company communications to obtain detailed insights into Regeneron's strategic priorities and execution plans for the upcoming 12-18 month period.
• Given the introductory nature of this excerpt and the absence of specific strategic details, investment decisions should not be based solely on this information; await further disclosures from the company or more comprehensive event coverage.